Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Columbia researchers have found that a protein released by multiple myeloma cells prevents the immune system from attacking the cancer, a finding that could lead to better treatments.
Researchers have found why cancer cells in oxygen-depleted environments are forced to rely on fat imports, a finding that could lead to new ways to understand and slow down tumor growth.
The program brings together physicians and nurse practitioners from multiple disciplines to provide care for smokers and ex-smokers who are at high risk for lung cancer and other complications.
Columbia geneticist Wendy Chung reflects on the progress made in cancer genetics and discusses the next frontier of using genetic information to design personalized cancer prevention strategies.
Columbia cancer researchers estimate that 60% of patients in a phase 2 clinical trial will have no sign of their cancer two years after treatment with combination therapy.